Market Movers (8-K)
Beacon Topco, Inc. and Clywedog Therapeutics have amended their merger agreement, pushing the closing date to October 31, 2026, while Clywedog announced positive Phase 1b trial results for its diabetes drug, balomenib.
Delay expected
Quarterly Earnings (10-Q)
Beacon Topco, Inc. files its Q2 2026 10-Q, detailing its formation and preparations for a business combination with Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc.